Free Trial

What is William Blair's Forecast for ALLO Q1 Earnings?

Allogene Therapeutics logo with Medical background
Remove Ads

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Allogene Therapeutics in a research note issued to investors on Friday, March 14th. William Blair analyst S. Corwin expects that the company will post earnings per share of ($0.29) for the quarter. The consensus estimate for Allogene Therapeutics' current full-year earnings is ($1.28) per share. William Blair also issued estimates for Allogene Therapeutics' Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.30) EPS and Q4 2026 earnings at ($0.30) EPS.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.06.

ALLO has been the topic of several other reports. Royal Bank of Canada restated an "outperform" rating and set a $10.00 price target on shares of Allogene Therapeutics in a report on Friday. Canaccord Genuity Group reaffirmed a "buy" rating and set a $14.00 price target on shares of Allogene Therapeutics in a research note on Friday. Finally, Citizens Jmp upgraded Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 price target for the company in a report on Friday. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Allogene Therapeutics has an average rating of "Moderate Buy" and an average target price of $9.40.

Remove Ads

Get Our Latest Analysis on ALLO

Allogene Therapeutics Stock Down 4.6 %

Shares of ALLO traded down $0.09 during mid-day trading on Monday, reaching $1.85. The company's stock had a trading volume of 3,372,618 shares, compared to its average volume of 3,035,002. The business has a fifty day moving average of $1.94 and a 200 day moving average of $2.31. The company has a market cap of $387.89 million, a price-to-earnings ratio of -1.19 and a beta of 1.02. Allogene Therapeutics has a 1 year low of $1.32 and a 1 year high of $4.74.

Institutional Investors Weigh In On Allogene Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ALLO. Cibc World Markets Corp bought a new stake in Allogene Therapeutics during the fourth quarter worth about $26,000. PAX Financial Group LLC bought a new stake in Allogene Therapeutics during the 4th quarter worth approximately $27,000. RPO LLC acquired a new stake in Allogene Therapeutics during the 4th quarter valued at $31,000. Caption Management LLC bought a new position in Allogene Therapeutics in the 4th quarter valued at $32,000. Finally, Syon Capital LLC acquired a new position in Allogene Therapeutics in the fourth quarter worth $39,000. Institutional investors and hedge funds own 83.63% of the company's stock.

Insider Activity

In related news, insider Timothy L. Moore sold 14,746 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $1.71, for a total value of $25,215.66. Following the completion of the transaction, the insider now owns 250,713 shares of the company's stock, valued at $428,719.23. This represents a 5.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Zachary Roberts sold 27,199 shares of Allogene Therapeutics stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total value of $48,414.22. Following the sale, the executive vice president now directly owns 488,054 shares in the company, valued at $868,736.12. The trade was a 5.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 52,710 shares of company stock valued at $92,125. 24.30% of the stock is owned by company insiders.

Allogene Therapeutics Company Profile

(Get Free Report)

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).

Featured Articles

Earnings History and Estimates for Allogene Therapeutics (NASDAQ:ALLO)

Should You Invest $1,000 in Allogene Therapeutics Right Now?

Before you consider Allogene Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allogene Therapeutics wasn't on the list.

While Allogene Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

AMD at Rock Bottom? Analysts Predict a MAJOR Rebound!

AMD at Rock Bottom? Analysts Predict a MAJOR Rebound!

AMD’s stock has dropped over 50% in the last 12 months, but is the worst over? Find out if AMD is set for a rebound—or if it’s still a falling knife.

Related Videos

Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
Is Micron on Par with AMD? BUY Now or DEAD Money?
AMD Stock’s Big Drop: Buy the Dip or More Pain Ahead?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads